These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

108 related items for PubMed ID: 9232213

  • 41. Sensitivity to cholecystokinin-tetrapeptide in major depression.
    Koszycki D, Copen J, Bradwejn J.
    J Affect Disord; 2004 Jun; 80(2-3):285-90. PubMed ID: 15207943
    [Abstract] [Full Text] [Related]

  • 42. CCK-4-induced anxiety but not panic is associated with serum brain-derived neurotrophic factor in healthy subjects.
    Maron E, Tõru I, Mäemets K, Sepp S, Vasar V, Shlik J, Zharkovsky A.
    J Psychopharmacol; 2009 Jun; 23(4):460-4. PubMed ID: 18562429
    [Abstract] [Full Text] [Related]

  • 43. Effect of oral ondansetron on total cholecystokinin plasma levels following CCK-4 panic challenge procedure in healthy men.
    Dépôt M, Merani S, Bradwejn J, Mukherjee J, Caillé J, Gutkowska J, Caillé G.
    J Psychiatry Neurosci; 1998 Nov; 23(5):298-304. PubMed ID: 9846035
    [Abstract] [Full Text] [Related]

  • 44. 10 microg CCK-4 premedication and 35% CO2 challenge in healthy volunteers.
    Schruers K, Pols H, Overbeek T, Griez E.
    Prog Neuropsychopharmacol Biol Psychiatry; 2000 Apr; 24(3):409-18. PubMed ID: 10836489
    [Abstract] [Full Text] [Related]

  • 45. Panic induction with cholecystokinin-tetrapeptide (CCK-4) Increases plasma concentrations of the neuroactive steroid 3alpha, 5alpha tetrahydrodeoxycorticosterone (3alpha, 5alpha-THDOC) in healthy volunteers.
    Eser D, di Michele F, Zwanzger P, Pasini A, Baghai TC, Schüle C, Rupprecht R, Romeo E.
    Neuropsychopharmacology; 2005 Jan; 30(1):192-5. PubMed ID: 15467707
    [Abstract] [Full Text] [Related]

  • 46. Central cholecystokinin activity in irritable bowel syndrome, panic disorder, and healthy controls.
    Koszycki D, Torres S, Swain JE, Bradwejn J.
    Psychosom Med; 2005 Jan; 67(4):590-5. PubMed ID: 16046372
    [Abstract] [Full Text] [Related]

  • 47. Effects of CCK-tetrapeptide in patients with social phobia and obsessive-compulsive disorder.
    Katzman MA, Koszycki D, Bradwejn J.
    Depress Anxiety; 2004 Jan; 20(2):51-8. PubMed ID: 15390214
    [Abstract] [Full Text] [Related]

  • 48. Behavioral, cardiovascular, and neuroendocrine profiles following CCK-4 challenge in healthy volunteers: a comparison of panickers and nonpanickers.
    Koszycki D, Zacharko RM, Le Mellédo JM, Bradwejn J.
    Depress Anxiety; 1998 Jan; 8(1):1-7. PubMed ID: 9750972
    [Abstract] [Full Text] [Related]

  • 49. Decrease in short-term memory function induced by CCK-4 in healthy volunteers.
    Shlik J, Koszycki D, Bradwejn J.
    Peptides; 1998 Jan; 19(6):969-75. PubMed ID: 9700743
    [Abstract] [Full Text] [Related]

  • 50. Copeptin - A potential endocrine surrogate marker of CCK-4-induced panic symptoms?
    Demiralay C, Agorastos A, Yassouridis A, Jahn H, Wiedemann K, Kellner M.
    Psychoneuroendocrinology; 2017 Feb; 76():14-18. PubMed ID: 27871026
    [Abstract] [Full Text] [Related]

  • 51. Therapeutic doses of neostigmine, depolarising neuromuscular blockade and muscle weakness in awake volunteers: a double-blind, placebo-controlled, randomised volunteer study.
    Kent NB, Liang SS, Phillips S, Smith NA, Khandkar C, Eikermann M, Stewart PA.
    Anaesthesia; 2018 Sep; 73(9):1079-1089. PubMed ID: 30132821
    [Abstract] [Full Text] [Related]

  • 52. Evaluation of the CCK-4 model as a challenge paradigm in a population of healthy volunteers within a proof-of-concept study.
    Eser D, Schüle C, Baghai T, Floesser A, Krebs-Brown A, Enunwa M, de la Motte S, Engel R, Kucher K, Rupprecht R.
    Psychopharmacology (Berl); 2007 Jul; 192(4):479-87. PubMed ID: 17318504
    [Abstract] [Full Text] [Related]

  • 53. Acute and chronic role of 5-HT3 neuronal system on behavioral and neuroendocrine changes induced by intravenous cholecystokinin tetrapeptide administration in humans.
    Dépôt M, Caillé G, Mukherjee J, Katzman MA, Cadieux A, Bradwejn J.
    Neuropsychopharmacology; 1999 Feb; 20(2):177-87. PubMed ID: 9885797
    [Abstract] [Full Text] [Related]

  • 54. A placebo-controlled trial of L-365,260, a CCKB antagonist, in panic disorder.
    Kramer MS, Cutler NR, Ballenger JC, Patterson WM, Mendels J, Chenault A, Shrivastava R, Matzura-Wolfe D, Lines C, Reines S.
    Biol Psychiatry; 1995 Apr 01; 37(7):462-6. PubMed ID: 7786960
    [Abstract] [Full Text] [Related]

  • 55. Copeptin in CCK-4-induced panic in healthy man: Sexual dimorphisms in secretion pattern and panic response, but no correlation of copeptin with panic symptoms.
    Kellner M, Zwanzger P, Rupprecht R, Eser D, Yassouridis A, Wiedemann K.
    Psychoneuroendocrinology; 2019 Dec 01; 110():104433. PubMed ID: 31525566
    [Abstract] [Full Text] [Related]

  • 56. CCK4-induced panic in healthy subjects I: psychological and cardiovascular effects.
    Jerabek I, Boulenger JP, Bradwejn J, Lavallée YJ, Jolicoeur FB.
    Eur Neuropsychopharmacol; 1999 Jan 01; 9(1-2):149-55. PubMed ID: 10082241
    [Abstract] [Full Text] [Related]

  • 57. Pentagastrin infusions in patients with panic disorder. I. Symptoms and cardiovascular responses.
    Abelson JL, Nesse RM.
    Biol Psychiatry; 1994 Jul 15; 36(2):73-83. PubMed ID: 7948449
    [Abstract] [Full Text] [Related]

  • 58. Cholecystokinin and panic disorder: past and future clinical research strategies.
    Bradwejn J, Koszycki D.
    Scand J Clin Lab Invest Suppl; 2001 Jul 15; 234():19-27. PubMed ID: 11713976
    [Abstract] [Full Text] [Related]

  • 59. CCK-B receptor gene and response to cholecystokinin-tetrapeptide in healthy volunteers.
    Koszycki D, Prichard Z, Fiocco AJ, Shlik J, Kennedy JL, Bradwejn J.
    Peptides; 2012 May 15; 35(1):9-13. PubMed ID: 22414867
    [Abstract] [Full Text] [Related]

  • 60. Effect of the selective serotonin reuptake inhibitor fluvoxamine on CCK-4 induced panic attacks.
    van Megen HJ, Westenberg HG, den Boer JA, Slaap B, Scheepmakers A.
    Psychopharmacology (Berl); 1997 Feb 15; 129(4):357-64. PubMed ID: 9085405
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.